Total for the last 12 months
number of access : ?
number of downloads : ?
ID 118611
Author
Kunishige, Michihiro National Hospital Organization Kochi Hospital
Ichihara, Seiya National Hospital Organization Kochi Hospital
Kadota, Naoki National Hospital Organization Kochi Hospital
Okano, Yoshio National Hospital Organization Kochi Hospital
Machida, Hisanori National Hospital Organization Kochi Hospital
Hatakeyama, Nobuo National Hospital Organization Kochi Hospital
Naruse, Keishi National Hospital Organization Kochi Hospital
Takeuchi, Eiji National Hospital Organization Kochi Hospital
Keywords
afatinib
CTNNB1 mutation
E709X
L858R
non–small cell lung cancer
Content Type
Journal Article
Description
Lung cancer with complex epidermal growth factor receptor (EGFR) and CTNNB1 comutations is rare, and the efficacy of tyrosine kinase inhibitors (TKIs) is generally poor. Here, we encountered a lung cancer patient with complex EGFR (L858R and E709X) and CTNNB1 comutations who successfully responded to afatinib. A 78-year-old woman visited our hospital with a cough and bloody sputum that had worsened over the past year. She had multiple mass shadows in both lungs and nodular shadows in the bronchi. The patient was diagnosed with lung adenocarcinoma cT4N3M1c stage IVB. A genetic analysis of the primary tumor using the Oncomine Dx target test multi-CDx system revealed positivity for EGFR (L858R and E709X) and CTNNB1 mutations. The expression of programmed death ligand 1 (22C3 clones) in tumor cells was negative by immunostaining. The patient was treated with afatinib as first-line therapy and achieved clinical improvement and a partial response and is continuing treatment 1 year later. Case reports of lung cancer patients with EGFR/CTNNB1 comutations are rare, and TKIs are not considered to be effective. We herein present the first case report of lung cancer with the co-occurrence of uncommon and complex EGFR (L858R and E709X) and CTNNB1 mutations that was successfully treated with afatinib.
Journal Title
Thoracic Cancer
ISSN
17597714
17597706
Publisher
China Lung Oncology Group|John Wiley & Sons Australia
Volume
14
Issue
4
Start Page
423
End Page
426
Published Date
2022-12-15
Rights
This is an open access article under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
EDB ID
DOI (Published Version)
URL ( Publisher's Version )
FullText File
language
eng
TextVersion
Publisher
departments
Medical Sciences